PDCD1 and melanoma: In another retrospective analysis of from two randomized KEYNOTE trials of anti-PD-1 (pembrolizumab) in melanoma and NSCLC patients (n=1144), decreased OS was observed in patients with higher pembrolizumab baseline clearance (melanoma HR = 2.56; 95% CI [1.72-3.80] and NSCLC HR = 2.64; 95% CI [1.94-3.57]), a finding that was positively associated with markers of cachexia (59).